Bayer Cropscience (BAYERCROP)₹3,484+2.60%Pesticides & Agrochemicals
In the Jun 2026 quarter (standalone), Bayer Cropscience reported sales of ₹1,836 Cr, down 4.2% from Jun 2025, and net profit of ₹323 Cr, up 15.5% year on year. For the year to Mar 2026, sales were ₹5,680 Cr and net profit ₹691 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,618 | 955 | 793 | 1,631 | 1,740 | 1,058 | 1,046 | 1,917 | 1,554 | 1,106 | 1,102 | 1,836 |
| Expenses | 1,307 | 824 | 692 | 1,312 | 1,547 | 1,033 | 872 | 1,561 | 1,342 | 985 | 895 | 1,461 |
| Operating Profit | 304 | 128 | 96.87 | 313 | 184 | 19.96 | 171 | 348 | 205 | 117 | 203 | 367 |
| OPM % | 19.0% | 13.0% | 12.0% | 19.0% | 11.0% | 1.9% | 16.0% | 18.0% | 13.0% | 11.0% | 18.0% | 20.0% |
| Other Income | 15.97 | 14.99 | 28.97 | 26.97 | 23.97 | 31.97 | 36.97 | 18.98 | 13.99 | 15.97 | 46.94 | 88.88 |
| Interest | 3.99 | 2.99 | 4.98 | 3.98 | 2.99 | 3.99 | 5.98 | 4.98 | 3.99 | 4.98 | 5.98 | 3.99 |
| Depreciation | 11.96 | 14.95 | 15.95 | 21.95 | 13.97 | 14.96 | 33.89 | 26.93 | 13.95 | 14.95 | 37.90 | 49.87 |
| Profit before tax | 305 | 124 | 105 | 315 | 189 | 33.90 | 168 | 334 | 199 | 113 | 205 | 401 |
| Tax % | 27.0% | 24.9% | 9.0% | 19.9% | 28.0% | −2.0% | 15.0% | 16.9% | 23.9% | 14.9% | 21.0% | 19.9% |
| Net Profit | 224 | 93.18 | 96.18 | 255 | 136 | 34.11 | 143 | 280 | 153 | 96.19 | 162 | 323 |
| EPS (Rs) | 49.48 | 20.67 | 21.30 | 56.38 | 30.25 | 7.59 | 31.79 | 61.86 | 33.86 | 21.24 | 35.95 | 71.40 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,771 | 2,805 | 2,710 | 3,167 | 3,608 | 4,263 | 4,739 | 5,139 | 5,112 | 5,472 | 5,680 | 5,598 |
| Expenses | 2,324 | 2,379 | 2,291 | 2,675 | 2,873 | 3,436 | 3,908 | 4,198 | 4,130 | 4,764 | 4,784 | 4,683 |
| Operating Profit | 434 | 413 | 409 | 482 | 724 | 810 | 811 | 923 | 958 | 690 | 872 | 891 |
| OPM % | 16.0% | 15.0% | 15.0% | 15.0% | 20.0% | 19.0% | 17.0% | 18.0% | 19.0% | 13.0% | 15.0% | 15.9% |
| Other Income | 81.91 | 69.87 | 38.93 | 50.92 | −63.87 | 68.94 | 112 | 168 | 75.93 | 118 | 94.88 | 166 |
| Interest | 9.98 | 6.97 | 10.96 | 9.97 | 13.94 | 12.96 | 12.97 | 21.93 | 19.92 | 16.96 | 19.95 | 18.94 |
| Depreciation | 24.95 | 28.90 | 32.88 | 43.87 | 64.79 | 73.73 | 63.79 | 79.77 | 73.76 | 84.71 | 93.76 | 117 |
| Profit before tax | 480 | 447 | 403 | 479 | 582 | 792 | 845 | 987 | 938 | 705 | 853 | 918 |
| Tax % | 34.9% | 34.9% | 25.9% | 29.9% | 18.9% | 37.9% | 23.9% | 23.0% | 21.0% | 20.0% | 19.0% | — |
| Exceptional items | 0.99 | 0.99 | 0.00 | −0.99 | −95.68 | 6.98 | 43.86 | 79.77 | −1.99 | −0.99 | 0.00 | — |
| Net Profit | 316 | 292 | 301 | 338 | 475 | 494 | 647 | 760 | 741 | 569 | 691 | 735 |
| EPS (Rs) | 88.83 | 82.01 | 87.19 | 97.84 | 105.22 | 109.47 | 143.11 | 168.31 | 164.29 | 126.00 | 152.83 | 162.45 |
| Dividend payout % | 18.9% | 20.9% | 20.9% | 17.9% | 24.0% | 105.0% | 103.9% | 76.9% | 84.9% | 98.9% | 97.9% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 36.86 | 34.88 | 34.87 | 33.90 | 33.85 | 44.83 | 44.86 | 44.83 | 44.83 | 44.80 | 44.80 | 44.81 |
| Reserves | 1,992 | 1,801 | 2,018 | 1,741 | 2,201 | 2,526 | 2,501 | 2,476 | 2,662 | 2,800 | 2,802 | 2,916 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 25.95 | 85.83 | 73.81 | 46.88 | 105 | 81.79 |
| Other Liabilities | 742 | 596 | 770 | 757 | 1,311 | 1,259 | 1,663 | 1,742 | 1,893 | 1,703 | 2,288 | 2,650 |
| Total Liabilities | 2,771 | 2,434 | 2,823 | 2,533 | 3,545 | 3,830 | 4,235 | 4,349 | 4,673 | 4,595 | 5,239 | 5,692 |
| Fixed Assets | 322 | 290 | 342 | 334 | 440 | 468 | 425 | 468 | 462 | 414 | 470 | 458 |
| CWIP | 1.01 | 17.03 | 24.03 | 36.05 | 47.07 | 56.03 | 76.05 | 98.21 | 109 | 119 | 119 | 127 |
| Investments | 28.93 | 67.88 | 49.86 | 0.00 | 0.00 | 40.90 | 51.84 | 37.89 | 40.94 | 53.86 | 34.95 | 56.85 |
| Other Assets | 2,420 | 2,059 | 2,408 | 2,162 | 3,059 | 3,265 | 3,682 | 3,746 | 4,060 | 4,008 | 4,615 | 5,049 |
| Inventories | 567 | 667 | 771 | 743 | 1,162 | 968 | 1,330 | 1,516 | 1,812 | 1,551 | 2,370 | 2,144 |
| Trade receivables | 572 | 406 | 557 | 660 | 700 | 719 | 757 | 1,007 | 977 | 961 | 954 | 1,118 |
| Cash & equivalents | 1,131 | 763 | 839 | 418 | 583 | 1,072 | 1,212 | 787 | 868 | 1,165 | 894 | 1,422 |
| Total Assets | 2,771 | 2,434 | 2,823 | 2,533 | 3,545 | 3,830 | 4,235 | 4,349 | 4,673 | 4,595 | 5,239 | 5,692 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 200 | 206 | 157 | 121 | 433 | 667 | 687 | 216 | 609 | 953 | 262 | 1,080 |
| Cash from investing activity | 485 | 15.98 | −7.99 | 38.01 | −113 | −28.99 | 7.01 | 63.99 | 83.03 | 0.00 | 85.98 | 71.95 |
| Cash from financing activity | −42.04 | −591 | −73.13 | −582 | −158 | −148 | −556 | −704 | −614 | −657 | −620 | −625 |
| Net cash flow | 642 | −366 | 75.73 | −420 | 161 | 487 | 137 | −422 | 78.73 | 295 | −271 | 525 |
| Capex | 51.86 | 39.88 | 54.82 | 43.91 | 59.83 | 40.85 | 41.88 | 54.88 | 76.75 | 45.86 | 42.86 | 63.81 |
| Free cash flow | 298 | 170 | 108 | 80.32 | 379 | 640 | 658 | 169 | 539 | 914 | 223 | 1,018 |
| CFO / OP % | 76.0% | 86.1% | 74.0% | 53.0% | 132.0% | 110.0% | 105.1% | 59.0% | 92.0% | 113.1% | 61.0% | 142.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 56 | 52 | 71 | 88 | 80 | 72 | 64 | 76 | 68 | 68 | 62 | 71 |
| Inventory days | 84 | 168 | 177 | 174 | 293 | 205 | 225 | 234 | 267 | 221 | 318 | 288 |
| Days payable | 41 | 53 | 68 | 68 | 165 | 102 | 143 | 128 | 130 | 88 | 149 | 168 |
| Cash conversion cycle | 103 | 172 | 185 | 198 | 212 | 178 | 150 | 186 | 209 | 205 | 235 | 194 |
| Working capital days | 54 | 93 | 105 | 135 | 117 | 78 | 62 | 85 | 87 | 79 | 89 | 57 |
| ROCE % | 31.0% | 25.0% | 23.0% | 22.0% | 24.9% | 30.0% | 31.0% | 31.0% | 34.0% | 34.0% | 25.0% | 28.9% |
For the Jun 2026 quarter, Bayer Cropscience reported sales of ₹1,836 Cr, down 4.2% year on year and net profit of ₹323 Cr, up 15.5% year on year. The operating margin was 20.0%.
Bayer Cropscience's sales for the year to Mar 2026 were ₹5,680 Cr; over the last twelve months they were ₹5,598 Cr.
Net profit for the year to Mar 2026 was ₹691 Cr, and ₹735 Cr over the last twelve months. Earnings per share over the same trailing period were ₹162.45.
Bayer Cropscience reported borrowings of ₹81.79 Cr at Mar 2026, against cash and equivalents of ₹1,422 Cr.
Cash from operations was ₹1,080 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1,018 Cr.